{"id":"NCT01336621","sponsor":"GlaxoSmithKline","briefTitle":"Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Therapy in the Treatment of Adults With Partial-Onset Seizures (POS)","officialTitle":"A Multicentre, Open-Label, Long-Term, Safety and Tolerability Study of Retigabine Immediate Release (IR) in Adults With Partial-Onset Seizures (Extension of Study RGB113905)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-02-21","primaryCompletion":"2016-12-14","completion":"2017-09-13","firstPosted":"2011-04-18","resultsPosted":"2018-02-26","lastUpdate":"2020-03-11"},"enrollment":98,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy"],"interventions":[{"type":"DRUG","name":"Retigabine IR","otherNames":[]}],"arms":[{"label":"Retigabine IR","type":"EXPERIMENTAL"}],"summary":"The purpose of this Phase III study is to assess the long-term safety, tolerability and efficacy of flexibly dosed retigabine Immediate Release (IR) as adjunctive therapy in adult subjects with partial-onset seizures. In addition, those subjects who successfully completed 20 weeks of adjunctive treatment with retigabine IR in the parent study, RGB113905, and who were thought to have benefitted from treatment will be provided continued access to retigabine IR.","primaryOutcome":{"measure":"Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious AEs (TESAEs): Safety Population","timeFrame":"Up to 5.8 years","effectByArm":[{"arm":"Retigabine IR","deltaMin":38,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":7},"locations":{"siteCount":31,"countries":["Belgium","Bulgaria","France","Germany","Italy","Netherlands","Poland","Russia","Thailand","Ukraine"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":98},"commonTop":["Dizziness","Asthenia","Headache","Weight increased","Bacteriuria"]}}